GFH312 / GenFleet Therap - LARVOL DELTA

A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC) (clinicaltrials.gov) - P2 | N=0 | Withdrawn | Sponsor: Zhejiang Genfleet Therapeutics Co., Ltd. | N=100 ➔ 0 | Recruiting ➔ Withdrawn

Enrollment change • Trial withdrawal • Cardiovascular • Peripheral Arterial Disease

A Randomized, Double-blind, Placebo-controlled, Single-dose and Multiple-dose Healthy Chinese Subjects (clinicaltrials.gov) - P1 | N=26 | Completed | Sponsor: Zhejiang Genfleet Therapeutics Co., Ltd.

New P1 trial

A Phase I Randomized, Double-Blinded, Placebo-Controlled Study Assessing the Safety and Pharmacokinetics of RIPK1 Inhibitor GFH312 in Healthy Subjects. (PubMed, Clin Transl Sci) - "In conclusion, GFH312 was well tolerated and demonstrated RIPK1 inhibition in healthy subjects. Ongoing studies will inform the use of GFH312 in potential indications."

Clinical • Journal • P1 data • PK/PD data • CNS Disorders • Inflammation • Pain • RIPK1

A Study of GFH312 in Healthy Subjects (clinicaltrials.gov) - P1 | N=76 | Completed | Sponsor: GenFleet Therapeutics (Australia) Pty Ltd. | Recruiting ➔ Completed

Trial completion

A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC) (clinicaltrials.gov) - P2 | N=100 | Recruiting | Sponsor: Zhejiang Genfleet Therapeutics Co., Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Peripheral Arterial Disease

A Study of GFH312 in Patients With Peripheral Artery Disease (PAD) and Intermittent Claudication (IC) (clinicaltrials.gov) - P2 | N=100 | Not yet recruiting | Sponsor: Zhejiang Genfleet Therapeutics Co., Ltd.

New P2 trial • Cardiovascular • Peripheral Arterial Disease

A Study of GFH312 in Healthy Subjects (clinicaltrials.gov) - P1; N=88; Recruiting; Sponsor: GenFleet Therapeutics (Australia) Pty Ltd.; Trial completion date: Mar 2022 ➔ Aug 2022; Trial primary completion date: Dec 2021 ➔ May 2022

Clinical • Trial completion date • Trial primary completion date